The introduction of nicotinamide as being a nicotine substitution in e-cigarette and smokeless products and solutions signifies a major regulatory obstacle to the FDA. Nicotinamide doesn't have nicotinic receptor agonist action and is known to act as a sedative at substantial dosages6. The statements created by Nicotine River, ECBlend, as well as o